Curis, Inc., incorporated on February 14, 2000, is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. Specifically, CUDC-907 inhibits HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. Inhibitors of HDAC enzymes can affect a number of cell functions and cancer cell viability by regulating the acetylation of both histone and non-histone substrates. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation.
CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways. These signaling pathways are shown to be involved in certain human cancers and inflammatory diseases. CA-4948 is a potent inhibitor of IRAK4 in biochemical and cell-based assays, as well as in an in vivo tumor model of diffuse large B cell lymphoma that harbors mutation in the IRAK4 pathway.
CA-327 is an oral small molecule drug candidate that is designed to selectively target PDL1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. Erivedge is an orally bioavailable small molecule, which is designed to inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened.
CUDC-427 is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. CUDC-305 is an oral HSP90 inhibitor.
The Company competes with Novartis International AG, Merck & Company, Celgene Corporation, Spectrum Pharmaceuticals, Sanofi, Mirati Therapeutics, Syndax Pharmaceuticals, Inc., MEI Pharma, Inc., Regenacy Pharmaceuticals, LLC, Italfarmaco S.p.A., Celleron Therapeutics, Gilead Sciences, Inc., Bayer AG, Genentech/Roche, Verastem, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Pfizer, Inc., TG Therapeutics, Inc., Incyte Corporation, Zenyaku Kogyo Co., Ltd, Nimbus Discovery, Amgen, Bristol-Myers Squibb, Merck KGaA, AstraZeneca/MedImmune, Tesaro/Anaptys Bio, Eli Lilly and Company, Exelixis, Inc., Pelle Pharm Inc., Senhwa Biosciences Inc., Debiopharm SA, TMedivir AB, Astex Therapeutics Ltd., Vernalis and Medivir AB.
4 Maguire Rd
The company trades on NASDAQ exchange. The company headquarter is located in Massachusetts, MA. The company was established in the 2000.| Ticker | CRIS |
| Long Name | Curis, Inc. |
| Short Name | Curis |